|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Recent studies have expanded the concept to include MYC/BCL2 protein co-expressing lymphomas.
|
25529575 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
These data indicate that blood BCL2-MBR translocations represent lymphoma precursor clones with malignant potential.
|
25549806 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e.
|
25827211 |
2015 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Some cases that have a similar clinical course with concomitant overexpression of MYC or BCL2 proteins were recently characterised as immunohistochemical double-hit lymphomas (ie, double-protein-expression lymphomas [DPLs]).
|
26545844 |
2015 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Accordingly, BCL2 mutations can affect antiapoptotic Bcl-2 function, are associated with increased activation-induced cytidine deaminase expression, and correlate with increased risk of transformation and death due to lymphoma.
|
25452615 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In conclusion, BCL2 translocation is a rare cytogenetic abnormality in BL, and BL probably accounts for only a small fraction of MYC/BCL2 DH lymphomas.
|
26182827 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
However, DHL and DPL are not concordant, and it is unclear whether MYC and BCL2 aberrations have prognostic impact in DPL patients.
|
25828389 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
|
25103070 |
2015 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression).
|
26158410 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Upregulation of hClock enhanced the activity of the anti‑apoptotic gene phosphorpylated (p‑)AKT and inhibited the expression of the pro‑apoptotic gene B cell lymphoma‑2 (Bcl‑2)‑associated X protein and Bcl‑2 homology 3 interacting domain death agonist.
|
25625359 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
We have reported micro-SPECT/CT imaging of Mec-1 human lymphoma xenografts in SCID mice, using [(111)In]DOTA-anti-bcl-2-PNA-Tyr(3)-octreotate.
|
26239085 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In contrast, patients with MYC+/BCL2+/TP53- double-hit lymphomas (DHL) (28 months), MYC+/BCL2-/TP53+ lymphomas (10 months) or sole TP53 mutation/deletion (12 months) had a poor median OS.
|
26717387 |
2015 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In mouse models, MYC induces lymphomas, but requires cooperation with other lesions, including inactivation of the p53 pathway, structural alterations of BCL2 family members, or increased PI3K activity.
|
25199984 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
FOXP1, p53, and BCL2 positivity was associated with poor OS with both lymphoma types but OS with DLBCL was significantly lower than with MALT lymphoma.
|
24232982 |
2014 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.
|
24786774 |
2014 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Moreover, BCL2 mRNA molecules correlated with IgH mRNA molecules in individual cells both in t(14;18) lymphoma cell lines and in patient samples.
|
25303368 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
BCL2(+)/MYC(+) double-hit lymphomas more frequently showed a germinal center B-like gene expression profile.
|
24179151 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
These subsets have been associated with a poor patient outcome, with the data being strongest for MYC/BCL2 double hit lymphomas.
|
23892979 |
2013 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
To gain further insight into the biology of this enigmatic lymphoproliferation, we analyzed morphologic, phenotypic, cytogenetic and molecular features of tissue specimens manifesting a pattern of follicular colonization by Bcl-2(bright+)CD10(+) B-cells and associated lymphomas from 13 adults and evaluated their clinical outcomes.
|
23363648 |
2013 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These lymphomas are aggressive and show high proliferation rate due to the growth advantages provided by MYC and BCL2 translocation and overexpression.
|
23330001 |
2013 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The hMB humanized mouse model underscores the synergy of MYC and BCL2 in 'double-hit' lymphomas in human patients.
|
22484426 |
2013 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Bcl-2 protein overexpression was associated with inferior outcome in patients with germinal center subtype lymphoma, but multivariate analysis showed that this was dependent on BCL2 translocations.
|
22929980 |
2013 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Furthermore, ectopic expression of Bcl-X(L) (but not Bcl-2) in two B-lymphoma cell lines decreased their sensitivity to parthenolide-induced apoptosis.
|
22155272 |
2012 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Among many factors that contribute to TRAIL resistance, overexpression of Bcl-2 is commonly seen in many kinds of tumors, particularly in lymphoma.
|
21988644 |
2012 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumors with extra MYC signals plus IGH@BCL2 or MYC rearrangement plus extra BCL2 signals, respectively, appear to behave as poorly as MYC/BCL2 lymphomas, possibly expanding the disease spectrum.
|
22002575 |
2012 |